Please assess the completion status of the following clinical trial:

Trial Title: Metolazone As Early Add On Therapy For Acute Decompensated Heart Failure (MELT-HF)--A Single Center Pilot Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Current hospitalization for chronic congestive heart failure with admission up to 48 hours prior to inclusion.~* Chronic heart failure will be defined as requiring treatment for a minimum of 30 days prior to current admission, NYHA Class III or IV at the time of hospitalization, and left ventricular ejection fraction less than 40% within one year or evidence of heart failure with preserved ejection fraction and evidence of diastolic dysfunction on echocardiogram.~* Admitted with clinical decompensated heart failure based on history, physical exam, and parameters indicating extracellular volume expansion such as including JVP ≥ 8 cm of water and 1+ or greater peripheral edema~* Is able to be dosed with study medication within six (6) hours of first dose of IV diuretics~Exclusion Criteria:~* Baseline severe hypotension (Mean arterial pressure \< 55 mm Hg)~* Creatinine clearance less than 20 ml/min or creatinine greater than 2.5 mg/dl.~* Serum sodium less than 128 meq/L.~* Serum Potassium \< 3.0 meq/L.~* Known adverse reaction to metolazone~* Inability to take oral medications~* Severe Aortic Stenosis (AVA \< 0.8cm2)~* History of Hypertrophic obstructive cardiomyopathy~* Metastatic Carcinoma per history~* Severe COPD, FEV \< 1L~* Severe dyspnea requiring prolonged CPAP,BIPAP or intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental: Placebo (Type: PLACEBO_COMPARATOR): This group will receive all standard heart failure therapy and placebo pill.
- Experimental: Metolazone (Type: ACTIVE_COMPARATOR): This group will receive all standard heart failure therapy with addition of metolazone.

Based on this trial design, predict the completion outcome and termination type (if applicable).